News Archive

After the bursting of the pandemic biotech bubble, talk of industry consolidation was ubiquitous. The sector had pushed out too many IPOs during the go-go years, leading to too many public biotech companies, with sub-scale enterprises, and wasteful crowding in lots of therapeutic categories.

Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired by Takeda for $4 billion upfront. By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC.

This month we held our 2023 Annual General Meeting for our fund’s investors and our Atlas Venture Retreat with industry executives. As in the past, we’ve kicked off each of these meetings with our Year In Review. Watch the presentation at the link in this article.

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes, likely in the first quarter of 2024.

Triveni Bio has raised $92 million in a Series A financing round as it aims to move its atopic dermatitis antibody into the clinic.